Skip to main content

Regulating the genome surveillance system: miRNAs and the p53 super family

Apoptosis volume 15, pages 541–552 (2010)Cite this article

Abstract

The p53 gene super family consists of three members; TP53, TP63 and TP73, encoding proteins p53, p63 and p73. Whilst p63 appears to have an essential role in embryonic development with a less clear role in carcinogenesis, irregularities in p53 and p73 signalling are implicated in tumour formation. As such, p53 is a tumour suppressor which is mutated in over 50% cancers and p73 was recently formally classified as a tumour suppressor based on data showing p73 deficient mice generate spontaneous tumours similar to those observed in p53 null mice. Dysregulation of both p53 and p73 has been correlated with cancer progression in many cell types and although mutation of these genes is often observed, some form of p53/p73 deregulation likely occurs in all tumour cells. The discovery that complementary micro RNAs (miRNAs) are able to target both of these genes provides a potential new means of perturbing p53/p73 signalling networks in cancer cells. Here we summarise the current literature regarding the involvement of miRNAs in the modulation of p53 family proteins and cancer development and detail the use of in silico methods to reveal key miRNA targets.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

References

  1. Lukas J, Lukas C, Bartek J (2004) Mammalian cell cycle checkpoints: signalling pathways and their organization in space and time. DNA Repair (Amst) 3:997–1007

    Article  CAS  Google Scholar 

  2. Bartek J, Lukas J (2001) Pathways governing G1/S transition and their response to DNA damage. FEBS Lett 490:117–122

    PubMed  Article  CAS  Google Scholar 

  3. Schmitt CA, Fridman JS, Yang M, Baranov E, Hoffman RM, Lowe SW (2002) Dissecting p53 tumour suppressor functions in vivo. Cancer Cell 1:289–298

    PubMed  Article  CAS  Google Scholar 

  4. Megidish T, Xu JH, Xu CW (2002) Activation of p53 by protein inhibitor of activated Stat1 (PIAS1). J Biol Chem 277:8255–8259

    PubMed  Article  CAS  Google Scholar 

  5. Nelson V, Davis GE, Maxwell SA (2001) A putative protein inhibitor of activated STAT (PIASy) interacts with p53 and inhibits p53-mediated transactivation but not apoptosis. Apoptosis 6:221–234

    PubMed  Article  CAS  Google Scholar 

  6. Olsson A, Manzl C, Strasser A, Villunger A (2007) How important are post-translational modifications in p53 for selectivity in target-gene transcription and tumour suppression? Cell Death Differ 14:1561–1575

    PubMed  Article  CAS  Google Scholar 

  7. Scoumanne A, Chen X (2008) Protein methylation: a new mechanism of p53 tumour suppressor regulation. Histol Histopathol 23:1143–1149

    PubMed  CAS  Google Scholar 

  8. Siliciano JD, Canman CE, Taya Y, Sakaguchi K, Appella E, Kastan MB (1997) DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev 11:3471–3481

    PubMed  Article  CAS  Google Scholar 

  9. Huang J, Sengupta R, Espejo AB et al (2007) p53 is regulated by the lysine demethylase LSD1. Nature 449:105–108

    PubMed  Article  CAS  Google Scholar 

  10. Dominguez G, Garcia JM, Pena C et al (2006) DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F–1. J Clin Oncol 24:805–815

    PubMed  Article  CAS  Google Scholar 

  11. Grob TJ, Novak U, Maisse C et al (2001) Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ 8:1213–1223

    PubMed  Article  CAS  Google Scholar 

  12. Kartasheva NN, Contente A, Lenz-Stoppler C, Roth J, Dobbelstein M (2002) p53 induces the expression of its antagonist p73 Delta N, establishing an autoregulatory feedback loop. Oncogene 21:4715–4727

    PubMed  Article  CAS  Google Scholar 

  13. Sabatino MA, Previdi S, Broggini M (2007) In vivo evaluation of the role of DNp73 alpha protein in regulating the p53-dependent apoptotic pathway after treatment with cytotoxic drugs. Int J Cancer 120:506–513

    PubMed  Article  CAS  Google Scholar 

  14. Stiewe T, Theseling CC, Putzer BM (2002) Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis. J Biol Chem 277:14177–14185

    PubMed  Article  CAS  Google Scholar 

  15. Townsend PA, Scarabelli TM, Davidson SM, Knight RA, Latchman DS, Stephanou A (2004) STAT-1 interacts with p53 to enhance DNA damage-induced apoptosis. J Biol Chem 279:5811–5820

    PubMed  Article  CAS  Google Scholar 

  16. Vossio S, Palescandolo E, Pediconi N et al (2002) DN-p73 is activated after DNA damage in a p53-dependent manner to regulate p53-induced cell cycle arrest. Oncogene 21:3796–3803

    PubMed  Article  CAS  Google Scholar 

  17. Wang S, El-Deiry WS (2006) p73 or p53 directly regulates human p53 transcription to maintain cell cycle checkpoints. Cancer Res 66:6982–6989

    PubMed  Article  CAS  Google Scholar 

  18. Yu J, Baron V, Mercola D, Mustelin T, Adamson ED (2007) A network of p73, p53 and Egr1 is required for efficient apoptosis in tumor cells. Cell Death Differ 14:436–446

    PubMed  Article  CAS  Google Scholar 

  19. Zaika AI, Slade N, Erster SH et al (2002) DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med 196:765–780

    PubMed  Article  CAS  Google Scholar 

  20. Zuckerman V, Wolyniec K, Sionov RV, Haupt S, Haupt Y (2009) Tumour suppression by p53: the importance of apoptosis and cellular senescence. J Pathol 219:3–15

    PubMed  CAS  Google Scholar 

  21. Vousden KH, Ryan KM (2009) p53 and metabolism. Nat Rev Cancer 9:691–700

    PubMed  Article  CAS  Google Scholar 

  22. Polager S, Ginsberg D (2009) p53 and E2f: partners in life and death. Nat Rev Cancer 9:738–748

    PubMed  Article  CAS  Google Scholar 

  23. Menendez D, Inga A, Resnick MA (2009) The expanding universe of p53 targets. Nat Rev Cancer 9:724–737

    PubMed  Article  CAS  Google Scholar 

  24. Meek DW (2009) Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer 9:714–723

    PubMed  CAS  Google Scholar 

  25. Blaydes JP (2010) Cooperation between MDM2 and MDMX in the regulation of p53. In: Hupp T, Ayed A (eds). p53: Landes bioscience

  26. Marine JC, Francoz S, Maetens M, Wahl G, Toledo F, Lozano G (2006) Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ 13:927–934

    PubMed  Article  CAS  Google Scholar 

  27. Michael D, Oren M (2003) The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 13:49–58

    PubMed  Article  CAS  Google Scholar 

  28. Spange S, Wagner T, Heinzel T, Kramer OH (2009) Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol 41:185–198

    PubMed  Article  CAS  Google Scholar 

  29. Harris SL, Levine AJ (2005) The p53 pathway: positive and negative feedback loops. Oncogene 24:2899–2908

    PubMed  Article  CAS  Google Scholar 

  30. Riley T, Sontag E, Chen P, Levine A (2008) Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 9:402–412

    PubMed  Article  CAS  Google Scholar 

  31. Levine B, Abrams J (2008) p53: the Janus of autophagy? Nat Cell Biol 10:637–639

    PubMed  Article  CAS  Google Scholar 

  32. Miyashita T, Reed JC (1995) Tumour suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293–299

    PubMed  Article  CAS  Google Scholar 

  33. Oda E, Ohki R, Murasawa H et al (2000) Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288:1053–1058

    PubMed  Article  CAS  Google Scholar 

  34. Nakano K, Vousden KH (2001) PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 7:683–694

    PubMed  Article  CAS  Google Scholar 

  35. Villunger A, Michalak EM, Coultas L et al (2003) p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 302:1036–1038

    PubMed  Article  CAS  Google Scholar 

  36. Michalak E, Villunger A, Erlacher M, Strasser A (2005) Death squads enlisted by the tumour suppressor p53. Biochem Biophys Res Commun 331:786–798

    PubMed  Article  CAS  Google Scholar 

  37. Munsch D, Watanabe-Fukunaga R, Bourdon JC et al (2000) Human and mouse Fas (APO-1/CD95) death receptor genes each contain a p53-responsive element that is activated by p53 mutants unable to induce apoptosis. J Biol Chem 275:3867–3872

    PubMed  Article  CAS  Google Scholar 

  38. Murray-Zmijewski F, Lane DP, Bourdon JC (2006) p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ 13:962–972

    PubMed  Article  CAS  Google Scholar 

  39. Kaghad M, Bonnet H, Yang A et al (1997) Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90:809–819

    PubMed  Article  CAS  Google Scholar 

  40. Scoumanne A, Harms KL, Chen X (2005) Structural basis for gene activation by p53 family members. Cancer Biol Ther 4:1178–1185

    PubMed  CAS  Google Scholar 

  41. Kaelin WG Jr (1999) The p53 gene family. Oncogene 18:7701–7705

    PubMed  Article  CAS  Google Scholar 

  42. Ishimoto O, Kawahara C, Enjo K, Obinata M, Nukiwa T, Ikawa S (2002) Possible oncogenic potential of Delta N p73: a newly identified isoform of human p73. Cancer Res 62:636–641

    PubMed  CAS  Google Scholar 

  43. Yang A, Walker N, Bronson R et al (2000) p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 404:99–103

    PubMed  Article  CAS  Google Scholar 

  44. Yang A, Kaghad M, Wang Y et al (1998) p63, a p53 homolog at 3q27–29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 2:305–316

    PubMed  Article  CAS  Google Scholar 

  45. Courtois S, Verhaegh G, North S et al (2002) Delta N-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene 21:6722–6728

    PubMed  Article  CAS  Google Scholar 

  46. Bourdon JC, Fernandes K, Murray-Zmijewski F et al (2005) p53 isoforms can regulate p53 transcriptional activity. Genes Dev 19:2122–2137

    PubMed  Article  CAS  Google Scholar 

  47. Rohaly G, Chemnitz J, Dehde S et al (2005) A novel human p53 isoform is an essential element of the ATR-intra-S phase checkpoint. Cell 122:21–32

    PubMed  Article  CAS  Google Scholar 

  48. De Laurenzi V, Costanzo A, Barcaroli D et al (1998) Two new p73 splice variants, gamma and delta, with different transcriptional activity. J Exp Med 188:1763–1768

    PubMed  Article  Google Scholar 

  49. De Laurenzi VD, Catani MV, Terrinoni A et al (1999) Additional complexity in p73: induction by mitogens in lymphoid cells and identification of two new splicing variants epsilon and zeta. Cell Death Differ 6:389–390

    PubMed  Article  CAS  Google Scholar 

  50. Ueda Y, Hijikata M, Takagi S, Chiba T, Shimotohno K (1999) New p73 variants with altered C-terminal structures have varied transcriptional activities. Oncogene 18:4993–4998

    PubMed  Article  CAS  Google Scholar 

  51. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408:307–310

    PubMed  Article  CAS  Google Scholar 

  52. Concin N, Hofstetter G, Berger A et al (2005) Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53–p73 cross-talk in vivo. Clin Cancer Res 11:8372–8383

    PubMed  Article  CAS  Google Scholar 

  53. Lanza M, Marinari B, Papoutsaki M et al (2006) Cross-talks in the p53 family: delta N p63 is an anti-apoptotic target for delta N p73alpha and p53 gain-of-function mutants. Cell Cycle 5:1996–2004

    PubMed  CAS  Google Scholar 

  54. Gartel AL (2008) Transcriptional inhibitors, p53 and apoptoss. Biochim Biophys Acta 1786:83–86

    PubMed  CAS  Google Scholar 

  55. He L, He X, Lim LP et al (2007) A microRNA component of the p53 tumour suppressor network. Nature 447:1130–1134

    PubMed  Article  CAS  Google Scholar 

  56. He X, He L, Hannon GJ (2007) The guardian’s little helper: microRNAs in the p53 tumour suppressor network. Cancer Res 67:11099–11101

    PubMed  Article  CAS  Google Scholar 

  57. Hermeking H (2007) p53 enters the microRNA world. Cancer Cell 12:414–418

    PubMed  Article  CAS  Google Scholar 

  58. Blandino G, Moll UM (2009) p63 regulation by microRNAs. Cell Cycle 8:1466–1467

    PubMed  CAS  Google Scholar 

  59. Ambros V (2004) The functions of animal microRNAs. Nature 431:350–355

    PubMed  Article  CAS  Google Scholar 

  60. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281–297

    PubMed  Article  CAS  Google Scholar 

  61. Lim LP, Glasner ME, Yekta S, Burge CB, Bartel DP (2003) Vertebrate microRNA genes. Science 299:1540

    PubMed  Article  CAS  Google Scholar 

  62. Lee RC, Feinbaum RL, Ambros V (1993) The C. elegans heterochronic gene line-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75:843–854

    PubMed  Article  CAS  Google Scholar 

  63. Esquela-Kerscher A, Slack FJ (2006) Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer 6:259–269

    PubMed  Article  CAS  Google Scholar 

  64. Israel A, Sharan R, Ruppin E, Galun E (2009) Increased microRNA activity in human cancers. PLoS One 4:e6045

    PubMed  Article  CAS  Google Scholar 

  65. Calin GA, Cimmino A, Fabbri M et al (2008) MiR-15a and miR-16–1 cluster functions in human leukemia. Proc Natl Acad Sci USA 105:5166–5171

    PubMed  Article  Google Scholar 

  66. Calin GA, Dumitru CD, Shimizu M et al (2002) Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99:15524–15529

    PubMed  Article  CAS  Google Scholar 

  67. Mraz M, Malinova K, Kotaskova J et al (2009) miR-34a, miR-29c and miR-17–5p are downregulated in CLL patients with TP53 abnormalities. Leukemia 23:1159–1163

    PubMed  Article  CAS  Google Scholar 

  68. Mraz M, Pospisilova S, Malinova K, Slapak I, Mayer J (2009) MicroRNAs in chronic lymphocytic leukemia pathogenesis and disease subtypes. Leuk Lymphoma 50:506–509

    PubMed  Article  CAS  Google Scholar 

  69. Nicoloso MS, Kipps TJ, Croce CM, Calin GA (2007) MicroRNAs in the pathogeny of chronic lymphocytic leukaemia. Br J Haematol 139:709–716

    PubMed  Article  CAS  Google Scholar 

  70. Cimmino A, Calin GA, Fabbri M et al (2005) miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 102:13944–13949

    PubMed  Article  CAS  Google Scholar 

  71. Eis PS, Tam W, Sun L et al (2005) Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA 102:3627–3632

    PubMed  Article  CAS  Google Scholar 

  72. Inomata M, Tagawa H, Guo YM, Kameoka Y, Takahashi N, Sawada K (2009) MicroRNA-17–92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes. Blood 113:396–402

    PubMed  Article  CAS  Google Scholar 

  73. Lawrie CH, Soneji S, Marafioti T et al (2007) MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. Int J Cancer 121:1156–1161

    PubMed  Article  CAS  Google Scholar 

  74. Lu J, Getz G, Miska EA et al (2005) MicroRNA expression profiles classify human cancers. Nature 435:834–838

    PubMed  Article  CAS  Google Scholar 

  75. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70

    PubMed  Article  CAS  Google Scholar 

  76. Liu H, Kohane IS (2009) Tissue and process specific microRNA-mRNA co-expression in mammalian development and malignancy. PLoS One 4:e5436

    PubMed  Article  CAS  Google Scholar 

  77. Ventura A, Jacks T (2009) MicroRNAs and cancer: short RNAs go a long way. Cell 136:586–591

    PubMed  Article  CAS  Google Scholar 

  78. Ota A, Tagawa H, Karnan S et al (2004) Identification and characterization of a novel gene, C13orf25, as a target for 13q31–q32 amplification in malignant lymphoma. Cancer Res 64:3087–3095

    PubMed  Article  CAS  Google Scholar 

  79. Zenz T, Benner A, Dohner H, Stilgenbauer S (2008) Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway. Cell Cycle 7:3810–3814

    PubMed  CAS  Google Scholar 

  80. Tashiro S, Takechi M, Asou H et al (1992) Cytogenetic 2; 18 and 18; 22 translocation in chronic lymphocytic leukemia with juxtaposition of bcl-2 and immunoglobulin light chain genes. Oncogene 7:573–577

    PubMed  CAS  Google Scholar 

  81. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T (2002) Identification of tissue-specific microRNAs from mouse. Curr Biol 12:735–739

    PubMed  Article  CAS  Google Scholar 

  82. Faraoni I, Antonetti FR, Cardone J, Bonmassar E (2009) miR-155 gene: a typical multifunctional microRNA. Biochim Biophys Acta 1792:497–505

    PubMed  CAS  Google Scholar 

  83. Taganov KD, Boldin MP, Chang KJ, Baltimore D (2006) NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signalling proteins of innate immune responses. Proc Natl Acad Sci USA 103:12481–12486

    PubMed  Article  CAS  Google Scholar 

  84. O’Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D (2007) MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci USA 104:1604–1609

    PubMed  Article  CAS  Google Scholar 

  85. Kluiver J, Poppema S, de Jong D et al (2005) BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol 207:243–249

    PubMed  Article  CAS  Google Scholar 

  86. Mendell JT (2008) miRiad roles for the miR-17–92 cluster in development and disease. Cell 133:217–222

    PubMed  Article  CAS  Google Scholar 

  87. O’Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT (2005) c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435:839–843

    PubMed  Article  CAS  Google Scholar 

  88. He L, Thomson JM, Hemann MT et al (2005) A microRNA polycistron as a potential human oncogene. Nature 435:828–833

    PubMed  Article  CAS  Google Scholar 

  89. Ivanovska I, Ball AS, Diaz RL et al (2008) MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression. Mol Cell Biol 28:2167–2174

    PubMed  Article  CAS  Google Scholar 

  90. Boren T, Xiong Y, Hakam A et al (2009) MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 113:249–255

    PubMed  Article  CAS  Google Scholar 

  91. Le MT, Teh C, Shyh-Chang N et al (2009) MicroRNA-125b is a novel negative regulator of p53. Genes Dev 23:862–876

    PubMed  Article  CAS  Google Scholar 

  92. Bommer GT, Gerin I, Feng Y et al (2007) p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 17:1298–1307

    PubMed  Article  CAS  Google Scholar 

  93. Braun CJ, Zhang X, Savelyeva I et al (2008) p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest. Cancer Res 68:10094–10104

    PubMed  Article  CAS  Google Scholar 

  94. Brosh R, Shalgi R, Liran A et al (2008) p53-Repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation. Mol Syst Biol 4:229

    PubMed  Article  CAS  Google Scholar 

  95. Chang TC, Wentzel EA, Kent OA et al (2007) Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 26:745–752

    PubMed  Article  CAS  Google Scholar 

  96. Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY (2007) MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res 67:8433–8438

    PubMed  Article  CAS  Google Scholar 

  97. Georges SA, Biery MC, Kim SY et al (2008) Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215. Cancer Res 68:10105–10112

    PubMed  Article  CAS  Google Scholar 

  98. Ji Q, Hao X, Meng Y et al (2008) Restoration of tumour suppressor miR-34 inhibits human p53-mutant gastric cancer tumour spheres. BMC Cancer 8:266

    PubMed  Article  CAS  Google Scholar 

  99. Sachdeva M, Zhu S, Wu F et al (2009) p53 represses c-Myc through induction of the tumour suppressor miR-145. Proc Natl Acad Sci USA 106:3207–3212

    PubMed  Article  Google Scholar 

  100. Tarasov V, Jung P, Verdoodt B et al (2007) Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 6:1586–1593

    PubMed  CAS  Google Scholar 

  101. Tili E, Michaille JJ, Cimino A et al (2007) Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol 179:5082–5089

    PubMed  CAS  Google Scholar 

  102. Mendes ND, Freitas AT, Sagot MF (2009) Current tools for the identification of miRNA genes and their targets. Nucleic Acids Res 37:2419–2433

    PubMed  Article  CAS  Google Scholar 

  103. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB (2003) Prediction of mammalian microRNA targets. Cell 115:787–798

    PubMed  Article  CAS  Google Scholar 

  104. Griffiths-Jones S (2004) The microRNA Registry. Nucleic Acids Res 32:D109–D111

    PubMed  Article  CAS  Google Scholar 

  105. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ (2008) miRBase: tools for microRNA genomics. Nucleic Acids Res 36:D154–D158

    PubMed  Article  CAS  Google Scholar 

  106. Enright AJ, John B, Gaul U, Tuschl T, Sander C, Marks DS (2003) MicroRNA targets in Drosophila. Genome Biol 5:R1

    PubMed  Article  Google Scholar 

  107. Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E (2007) The role of site accessibility in microRNA target recognition. Nat Genet 39:1278–1284

    PubMed  Article  CAS  Google Scholar 

  108. Iliopoulos D, Malizos KN, Oikonomou P, Tsezou A (2008) Integrative microRNA and proteomic approaches identify novel osteoarthritis genes and their collaborative metabolic and inflammatory networks. PLoS One 3:e3740

    PubMed  Article  CAS  Google Scholar 

  109. Pandey DP, Picard D (2009) miR-22 inhibits estrogen signalling by directly targeting the estrogen receptor alpha mRNA. Mol Cell Biol 29:3783–3790

    PubMed  Article  CAS  Google Scholar 

  110. Tan LP, Wang M, Robertus JL et al (2009) miRNA profiling of B-cell subsets: specific miRNA profile for germinal centre B cells with variation between centroblasts and centrocytes. Lab Invest 89:708–716

    PubMed  Article  CAS  Google Scholar 

  111. Lodygin D, Tarasov V, Epanchintsev A et al (2008) Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 7:2591–2600

    PubMed  CAS  Google Scholar 

  112. Collado M, Blasco MA, Serrano M (2007) Cellular senescence in cancer and aging. Cell 130:223–233

    PubMed  Article  CAS  Google Scholar 

  113. Hermeking H (2009) MiR-34a and p53. Cell Cycle 8:1308

    PubMed  Google Scholar 

  114. Raver-Shapira N, Oren M (2007) Tiny actors, great roles: microRNAs in p53’s service. Cell Cycle 6:2656–2661

    PubMed  CAS  Google Scholar 

  115. Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K (2009) Modulation of microRNA processing by p53. Nature 460:529–533

    PubMed  Article  CAS  Google Scholar 

  116. Goldschneider D, Horvilleur E, Plassa LF et al (2006) Expression of C-terminal deleted p53 isoforms in neuroblastoma. Nucleic Acids Res 34:5603–5612

    PubMed  Article  CAS  Google Scholar 

  117. Boldrup L, Bourdon JC, Coates PJ, Sjostrom B, Nylander K (2007) Expression of p53 isoforms in squamous cell carcinoma of the head and neck. Eur J Cancer 43:617–623

    PubMed  Article  CAS  Google Scholar 

  118. Ebrahimi M, Boldrup L, Coates PJ, Wahlin YB, Bourdon JC, Nylander K (2008) Expression of novel p53 isoforms in oral lichen planus. Oral Oncol 44:156–161

    PubMed  Article  CAS  Google Scholar 

  119. Avery-Kiejda KA, Zhang XD, Adams LJ et al (2008) Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin. Clin Cancer Res 14:1659–1668

    PubMed  Article  CAS  Google Scholar 

  120. Chen J, Ng SM, Chang C et al (2009) p53 isoform delta113p53 is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafish. Genes Dev 23:278–290

    PubMed  Article  CAS  Google Scholar 

  121. Baffa R, Fassan M, Volinia S, et al. (2009) MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol

  122. Tong AW, Fulgham P, Jay C et al (2009) MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther 16:206–216

    PubMed  CAS  Google Scholar 

  123. Costanzo A, Merlo P, Pediconi N et al (2002) DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol Cell 9:175–186

    PubMed  Article  CAS  Google Scholar 

  124. Fillippovich I, Sorokina N, Gatei M et al (2001) Transactivation-deficient p73alpha (p73Deltaexon2) inhibits apoptosis and competes with p53. Oncogene 20:514–522

    PubMed  Article  CAS  Google Scholar 

  125. Irwin M, Marin MC, Phillips AC et al (2000) Role for the p53 homologue p73 in E2F–1-induced apoptosis. Nature 407:645–648

    PubMed  Article  CAS  Google Scholar 

  126. Jain N, Gupta S, Sudhakar C, Radha V, Swarup G (2005) Role of p73 in regulating human caspase-1 gene transcription induced by interferon-{gamma} and cisplatin. J Biol Chem 280:36664–36673

    PubMed  Article  CAS  Google Scholar 

  127. Melino G, Bernassola F, Ranalli M et al (2004) p73 Induces apoptosis via PUMA transactivation and Bax mitochondrial translocation. J Biol Chem 279:8076–8083

    PubMed  Article  CAS  Google Scholar 

  128. Zhu J, Nozell S, Wang J, Jiang J, Zhou W, Chen X (2001) p73 cooperates with DNA damage agents to induce apoptosis in MCF7 cells in a p53-dependent manner. Oncogene 20:4050–4057

    PubMed  Article  CAS  Google Scholar 

  129. Stiewe T, Putzer BM (2000) Role of the p53-homologue p73 in E2F1-induced apoptosis. Nat Genet 26:464–469

    PubMed  Article  CAS  Google Scholar 

  130. Cuadros M, Ribas G, Fernandez V, Rivas C, Benitez J, Martinez-Delgado B (2006) Allelic expression and quantitative RT-PCR study of TAp73 and DeltaNp73 in non-Hodgkin’s lymphomas. Leuk Res 30:170–177

    PubMed  Article  CAS  Google Scholar 

  131. Meier M, den Boer ML, Meijerink JP et al (2006) Differential expression of p73 isoforms in relation to drug resistance in childhood T-lineage acute lymphoblastic leukaemia. Leukemia 20:1377–1384

    PubMed  Article  CAS  Google Scholar 

  132. Concin N, Becker K, Slade N et al (2004) Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res 64:2449–2460

    PubMed  Article  CAS  Google Scholar 

  133. Marabese M, Marchini S, Marrazzo E et al (2008) Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer. Eur J Cancer 44:131–141

    PubMed  Article  CAS  Google Scholar 

  134. Muller M, Schilling T, Sayan AE et al (2005) TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ 12:1564–1577

    PubMed  Article  CAS  Google Scholar 

  135. Levy D, Adamovich Y, Reuven N, Shaul Y (2007) The Yes-associated protein 1 stabilizes p73 by preventing Itch-mediated ubiquitination of p73. Cell Death Differ 14:743–751

    PubMed  Article  CAS  Google Scholar 

  136. Oberst A, Rossi M, Salomoni P et al (2005) Regulation of the p73 protein stability and degradation. Biochem Biophys Res Commun 331:707–712

    PubMed  Article  CAS  Google Scholar 

  137. Rossi M, De Laurenzi V, Munarriz E et al (2005) The ubiquitin-protein ligase Itch regulates p73 stability. EMBO J 24:836–848

    PubMed  Article  CAS  Google Scholar 

  138. Sampath D, Calin GA, Puduvalli VK et al (2009) Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation. Blood 113:3744–3753

    PubMed  Article  CAS  Google Scholar 

  139. di Val Cervo PR, Tucci P, Majid A et al (2009) p73, miR106b, miR34a, and Itch in chronic lymphocytic leukemia. Blood 113:6498–6499 (author reply 6499–6500)

    Article  CAS  Google Scholar 

  140. Donehower LA, Harvey M, Slagle BL et al (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215–221

    PubMed  Article  CAS  Google Scholar 

  141. Nam EJ, Yoon H, Kim SW et al (2008) MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 14:2690–2695

    PubMed  Article  CAS  Google Scholar 

  142. Bellon M, Lepelletier Y, Hermine O, Nicot C (2009) Deregulation of microRNA involved in hematopoiesis and the immune response in HTLV-I adult T-cell leukemia. Blood 113:4914–4917

    PubMed  Article  CAS  Google Scholar 

  143. Lee KH, Chen YL, Yeh SD et al (2009) MicroRNA-330 acts as tumor suppressor and induces apoptosis of prostate cancer cells through E2F1-mediated suppression of Akt phosphorylation. Oncogene 28:3360–3370

    PubMed  Article  CAS  Google Scholar 

  144. Marabese M, Vikhanskaya F, Rainelli C, Sakai T, Broggini M (2003) DNA damage induces transcriptional activation of p73 by removing C-EBPalpha repression on E2F1. Nucleic Acids Res 31:6624–6632

    PubMed  Article  CAS  Google Scholar 

  145. Kozaki K, Imoto I, Mogi S, Omura K, Inazawa J (2008) Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 68:2094–2105

    PubMed  Article  CAS  Google Scholar 

  146. Reddy SD, Pakala SB, Ohshiro K, Rayala SK, Kumar R (2009) MicroRNA-661, a c/EBPalpha target, inhibits metastatic tumor antigen 1 and regulates its functions. Cancer Res 69:5639–5642

    PubMed  Article  CAS  Google Scholar 

  147. Ozaki T, Nakagawara A (2005) p73, a sophisticated p53 family member in the cancer world. Cancer Sci 96:729–737

    PubMed  Article  CAS  Google Scholar 

  148. Zhou L, Qi X, Potashkin JA, Abdul-Karim FW, Gorodeski GI (2008) MicroRNAs miR-186 and miR-150 down-regulate expression of the pro-apoptotic purinergic P2X7 receptor by activation of instability sites at the 3′-untranslated region of the gene that decrease steady-state levels of the transcript. J Biol Chem 283:28274–28286

    PubMed  Article  CAS  Google Scholar 

  149. Lin YC, Kuo MW, Yu J et al (2008) c-Myb is an evolutionary conserved miR-150 target and miR-150/c-Myb interaction is important for embryonic development. Mol Biol Evol 25:2189–2198

    PubMed  Article  CAS  Google Scholar 

  150. Tchatchou S, Jung A, Hemminki K et al (2009) A variant affecting a putative miRNA target site in estrogen receptor (ESR) 1 is associated with breast cancer risk in premenopausal women. Carcinogenesis 30:59–64

    PubMed  Article  CAS  Google Scholar 

  151. Chen X, Guo X, Zhang H et al (2009) Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 28:1385–1392

    PubMed  Article  CAS  Google Scholar 

  152. Cordes KR, Sheehy NT, White MP et al (2009) miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature 460:705–710

    PubMed  CAS  Google Scholar 

  153. Akao Y, Nakagawa Y, Iio A, Naoe T (2009) Role of microRNA-143 in Fas-mediated apoptosis in human T-cell leukemia Jurkat cells. Leuk Res 33:1530–1538

    PubMed  Article  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by Leukaemia Research.

Author information

Affiliations

  1. Human Genetics Division, School of Medicine, University of Southampton, Tremona Road, Southampton, SO16 6YD, UK

    Sarah G. Bailey & Paul A. Townsend

  2. Division of Infection, Inflammation and Immunity, School of Medicine, University of Southampton, Tremona Road, Southampton, SO16 6YD, UK

    Tilman Sanchez-Elsner

  3. Medical Molecular Biology Unit, Institute of Child Health, University College London, 30, Guilford Street, London, WC1N 1EH, UK

    Anastasis Stephanou

  4. Cancer Sciences Division, School of Medicine, University of Southampton, Tremona Road, Southampton, SO16 6YD, UK

    Mark S. Cragg

Authors
  1. Sarah G. Bailey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tilman Sanchez-Elsner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anastasis Stephanou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mark S. Cragg
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Paul A. Townsend
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul A. Townsend.

Additional information

Mark S Cragg and Paul A Townsend are the joint senior authors.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Bailey, S.G., Sanchez-Elsner, T., Stephanou, A. et al. Regulating the genome surveillance system: miRNAs and the p53 super family. Apoptosis 15, 541–552 (2010). https://doi.org/10.1007/s10495-010-0456-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10495-010-0456-1

Keywords

  • p73
  • miRNA
  • p53
  • Leukaemia
  • Lymphoma